Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis
- PMID: 19013463
- PMCID: PMC2628583
- DOI: 10.1053/j.gastro.2008.08.050
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis
Abstract
Background & aims: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in American children. Noninvasive means to discriminate between NAFLD and nonalcoholic steatohepatitis (NASH) might diminish the requirement for liver biopsy or predict those at increased risk for progression.
Methods: Data obtained prospectively from children (age, 6-17 y) enrolled in the NASH Clinical Research Network were analyzed to identify clinical-pathologic correlates of pediatric NAFLD. All participants underwent liver biopsy within 6 months of clinical data that were reviewed by a central pathology committee.
Results: A total of 176 children (mean age, 12.4 y; 77% male) were eligible for inclusion. By using ordinal logistic regression analysis, increasing aspartate aminotransferase (AST) level (odds ratio [OR], 1.017 per U/L; 95% confidence interval [CI], 1.004-1.031) and gamma-glutamyltransferase level (OR, 1.016 per U/L; 95% CI, 1.000-1.033) were associated independently with increasing severity of NASH. Increasing AST level (OR, 1.015 per U/L; 95% CI, 1.006-1.024), increasing white blood cell count (OR, 1.22 per 1000/mm(3); 95% CI, 1.07-1.38), and decreasing hematocrit (OR, 0.87 per %; 95% CI, 0.79-0.96) were associated independently with increasing severity of fibrosis. Area under the receiver operator characteristic curve for a model with AST and alanine aminotransferase was 0.75 (95% CI, 0.66-0.84) and 0.74 (95% CI, 0.63-0.85) for distinguishing steatosis from more advanced forms of NASH and bridging fibrosis from lesser degrees of fibrosis, respectively.
Conclusions: Certain components of routine laboratory tests are predictive of NAFLD pattern and fibrosis severity, but do not have adequate discriminate power to replace liver biopsy in evaluating pediatric NAFLD.
Figures
Comment in
-
The natural history of nonalcoholic fatty liver disease: insights from children and mice.Gastroenterology. 2008 Dec;135(6):1860-2. doi: 10.1053/j.gastro.2008.11.004. Epub 2008 Nov 8. Gastroenterology. 2008. PMID: 19000676 No abstract available.
Similar articles
-
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520. JAMA. 2011. PMID: 21521847 Free PMC article. Clinical Trial.
-
Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.J Pediatr. 2021 Dec;239:161-167.e5. doi: 10.1016/j.jpeds.2021.08.012. Epub 2021 Aug 13. J Pediatr. 2021. PMID: 34400208 Free PMC article. Clinical Trial.
-
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.Am J Gastroenterol. 2005 May;100(5):1082-90. doi: 10.1111/j.1572-0241.2005.41583.x. Am J Gastroenterol. 2005. PMID: 15842582 Clinical Trial.
-
Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.Curr Gastroenterol Rep. 2020 Aug 19;22(10):52. doi: 10.1007/s11894-020-00786-y. Curr Gastroenterol Rep. 2020. PMID: 32814993 Review.
-
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.J Hepatol. 2013 Sep;59(3):550-6. doi: 10.1016/j.jhep.2013.04.027. Epub 2013 May 9. J Hepatol. 2013. PMID: 23665288
Cited by
-
Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease.Korean J Pediatr. 2013 Feb;56(2):45-51. doi: 10.3345/kjp.2013.56.2.45. Epub 2013 Feb 25. Korean J Pediatr. 2013. PMID: 23482433 Free PMC article.
-
Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: A systematic review.Liver Int. 2021 Sep;41(9):2087-2100. doi: 10.1111/liv.14908. Epub 2021 May 11. Liver Int. 2021. PMID: 33894100 Free PMC article.
-
Clinical significance of serum alanine aminotransferase and lifestyle intervention in children with nonalcoholic fatty liver disease.Korean J Pediatr. 2016 Sep;59(9):362-367. doi: 10.3345/kjp.2016.59.9.362. Epub 2016 Sep 21. Korean J Pediatr. 2016. PMID: 27721840 Free PMC article.
-
Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease.Hepatol Commun. 2018 Sep 27;2(10):1213-1226. doi: 10.1002/hep4.1232. eCollection 2018 Oct. Hepatol Commun. 2018. PMID: 30288476 Free PMC article.
-
Fatty liver disease in an autopsy series of children and adolescents.Hippokratia. 2012 Jan;16(1):61-5. Hippokratia. 2012. PMID: 23930060 Free PMC article.
References
-
- Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–93. - PubMed
-
- Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:68–71. - PubMed
-
- Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40. - PubMed
-
- Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349–54. - PubMed
-
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1RR02501401/RR/NCRR NIH HHS/United States
- U01DK061713/DK/NIDDK NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- U01DK061731/DK/NIDDK NIH HHS/United States
- U01DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- U01DK061718/DK/NIDDK NIH HHS/United States
- RR02413101/RR/NCRR NIH HHS/United States
- U01DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- M01 RR000065/RR/NCRR NIH HHS/United States
- T32 DK007202/DK/NIDDK NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- M01RR020359/RR/NCRR NIH HHS/United States
- M01RR000827/RR/NCRR NIH HHS/United States
- U01DK061738/DK/NIDDK NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- M01RR000065/RR/NCRR NIH HHS/United States
- U01DK061732/DK/NIDDK NIH HHS/United States
- M01 RR000750/RR/NCRR NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- UL1RR024989/RR/NCRR NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- M01 RR000827/RR/NCRR NIH HHS/United States
- M01RR00188/RR/NCRR NIH HHS/United States
- U01DK061734/DK/NIDDK NIH HHS/United States
- U01DK061730/DK/NIDDK NIH HHS/United States
- M01 RR020359/RR/NCRR NIH HHS/United States
- M01RR000750/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical